

# Hassan Alkhateeb

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4124127/publications.pdf>

Version: 2024-02-01

130  
papers

752  
citations

623734

14  
h-index

677142

22  
g-index

131  
all docs

131  
docs citations

131  
times ranked

1090  
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of sublingual tacrolimus in adults undergoing hematopoietic cell transplant: A pilot study. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 387-394.	0.9	0
2	Membranous Nephropathy With Extensive Tubular Basement Membrane Deposits Following Allogeneic Hematopoietic Cell Transplant: A Report of 5 Cases. <i>American Journal of Kidney Diseases</i> , 2022, 79, 904-908.	1.9	9
3	Comparative study of therapy-related and de novo adult B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2022, 196, 963-968.	2.5	6
4	Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. <i>Blood Cancer Journal</i> , 2022, 12, 12.	6.2	1
5	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response. <i>Blood Cancer Journal</i> , 2022, 12, 7.	6.2	5
6	&lt;i>SF3B1</i>-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. <i>Haematologica</i> , 2022, 107, 1189-1192.	3.5	3
7	Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	10
8	Allogeneic Stem Cell Transplant Outcomes in Patients with DDX41 Mutated Myeloid Malignancies. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S126-S127.	1.2	1
9	Clinical Outcomes of Pretransplant Mortality Prediction Models in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S132-S133.	1.2	0
10	Factors Predicting Survival Following Allogeneic Stem Cell Transplant in Patients with Therapy-Related Myeloid Neoplasms. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S137-S138.	1.2	2
11	Elevated Pre-Transplant Ferritin Is Associated with Development of Liver Graft-Vs-Host Disease in Myelodysplastic Syndromes Following Allogeneic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S301-S302.	1.2	0
12	Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with $\geq 7+3$ . <i>Blood Cancer Journal</i> , 2022, 12, 55.	6.2	4
13	1113: IN-HOSPITAL RISK FACTORS FOR ACUTE RESPIRATORY DISTRESS SYNDROME AFTER BONE MARROW TRANSPLANTATION. <i>Critical Care Medicine</i> , 2022, 50, 555-555.	0.9	0
14	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). <i>Blood Cancer Journal</i> , 2022, 12, 62.	6.2	6
15	Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms. <i>American Journal of Hematology</i> , 2022, 97, 1013-1022.	4.1	7
16	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20mg twice daily or higher: A real-world experience. <i>British Journal of Haematology</i> , 2022, 198, .	2.5	7
17	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	6
18	Characteristics and prognosis of mutated <i>STAG2</i> myeloid neoplasms.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19014-e19014.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.. Journal of Clinical Oncology, 2022, 40, TPS7080-TPS7080.	1.6	0
20	Characteristics and prognosis of <i>DDX41</i>- and <i>GATA2</i>-mutated myeloid neoplasms.. Journal of Clinical Oncology, 2022, 40, e19010-e19010.	1.6	0
21	Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood Cancer Journal, 2022, 12, .	6.2	7
22	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. Transplantation and Cellular Therapy, 2021, 27, 165.e1-165.e11.	1.2	11
23	Risk of relapse in patients receiving azithromycin after allogeneic HSCT. Bone Marrow Transplantation, 2021, 56, 960-962.	2.4	3
24	Chronic graft-versus-host disease in pancreas after kidney transplant recipients â€œ An unrecognized entity. American Journal of Transplantation, 2021, 21, 883-888.	4.7	2
25	PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 764-767.	1.3	7
26	Pilot Study Characterizing the Hematology-Oncology Fellow Job Search Process: Tools Used and Identification of Potential New Resources. Journal of Cancer Education, 2021, , 1.	1.3	0
27	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia â€œ A Single Center Retrospective Study. Blood and Lymphatic Cancer: Targets and Therapy, 2021, Volume 11, 1-9.	2.7	8
28	Immuneâ€mediated neuromuscular complications of graftâ€versusâ€host disease. Muscle and Nerve, 2021, 63, 852-860.	2.2	7
29	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer Journal, 2021, 11, 49.	6.2	28
30	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer Journal, 2021, 11, 43.	6.2	11
31	Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal, 2021, 11, 63.	6.2	11
32	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. Blood Advances, 2021, 5, 2272-2278.	5.2	19
33	Venetoclax with azacitidine or decitabine in blastâ€phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. American Journal of Hematology, 2021, 96, 781-789.	4.1	46
34	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer Journal, 2021, 11, 122.	6.2	7
35	Hemoglobinuria in the early post stem cell transplant period: Risk factors and association with outcomes. Kidney360, 2021, 2, 10.34067/KID.0002262021.	2.1	0
36	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplantation, 2021, 56, 3068-3077.	2.4	13

#	ARTICLE	IF	CITATIONS
37	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 156.	6.2	4
38	Nelarabine-Induced Myelotoxicity. <i>Neurology</i> , 2021, 96, 175-176.	1.1	5
39	<i>JAK2</i> wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy. <i>Blood</i> , 2021, 138, 2886-2889.	1.4	12
40	Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy. <i>Blood</i> , 2021, 138, 36-36.	1.4	0
41	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. <i>Blood</i> , 2021, 138, 1267-1267.	1.4	0
42	Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents. <i>Blood</i> , 2021, 138, 219-219.	1.4	3
43	A novel Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction. <i>Blood Cancer Journal</i> , 2021, 11, 183.	6.2	0
44	Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). <i>Blood</i> , 2021, 138, 1096-1096.	1.4	0
45	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. <i>Blood</i> , 2021, 138, 3368-3368.	1.4	1
46	Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM). <i>Blood</i> , 2021, 138, 2285-2285.	1.4	0
47	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and <i>DDX41</i> Mutation: Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 3691-3691.	1.4	1
48	<i>DDX41</i> Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic <i>DDX41</i> : Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort. <i>Blood</i> , 2021, 138, 3693-3693.	1.4	2
49	T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML. <i>Blood</i> , 2021, 138, 3377-3377.	1.4	0
50	Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152. <i>Blood</i> , 2021, 138, 3407-3407.	1.4	5
51	Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy. <i>Blood</i> , 2021, 138, 568-568.	1.4	4
52	Hybridization capture-based next generation sequencing reliably detects <i>FLT3</i> mutations and classifies <i>FLT3</i> -internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. <i>Modern Pathology</i> , 2020, 33, 334-343.	5.5	18
53	Clinical utility of fluorescence in situ hybridization-based diagnosis of <i>BCR-ABL1</i> like (<sc>P</sc>hiladelphia chromosome like) <sc>B</sc>-acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, E68-E72.	4.1	4
54	Marked hypereosinophilia secondary to endometrioid ovarian cancer presenting with asthma symptoms, a case report. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101178.	0.4	2

#	ARTICLE	IF	CITATIONS
55	Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 121.	6.2	21
56	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
57	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. <i>American Journal of Hematology</i> , 2020, 95, 1511-1521.	4.1	83
58	Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. <i>Blood Advances</i> , 2020, 4, 5425-5430.	5.2	16
59	A population-based study of chronic neutrophilic leukemia in the United States. <i>Blood Cancer Journal</i> , 2020, 10, 68.	6.2	8
60	Characteristics of patients with myelodysplastic syndrome with balanced translocations. <i>British Journal of Haematology</i> , 2020, 190, 244-248.	2.5	1
61	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1592-1600.	1.3	17
62	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a "graft versus host"-like syndrome and poor outcomes. <i>Bone Marrow Transplantation</i> , 2020, 55, 1879-1881.	2.4	1
63	Low-Dose Total Body Irradiation (TBI) Use As Part of Pre-Transplant Conditioning Regimen Is Associated with Worse Outcomes in Patients with Severe Aplastic Anemia (SAA) Treated with Allogeneic Hematopoietic Stem Cell Transplantation (HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S251-S252.	2.0	0
64	A population-based study of chronic eosinophilic leukemia not otherwise specified in the United States. <i>American Journal of Hematology</i> , 2020, 95, E257.	4.1	6
65	Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1170-1179.	4.1	19
66	Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes. <i>Anticancer Research</i> , 2020, 40, 3883-3888.	1.1	2
67	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. <i>Annals of Hematology</i> , 2020, 99, 513-518.	1.8	1
68	Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR. <i>Blood</i> , 2020, 136, 28-29.	1.4	0
69	Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. <i>Blood</i> , 2020, 136, 26-27.	1.4	1
70	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. <i>Blood</i> , 2020, 136, 44-44.	1.4	0
71	Determination of Relapse Risk By Complement Gene Variants after Eculizumab Discontinuation in Complement-Mediated Thrombotic Microangiopathy: A Retrospective Review. <i>Blood</i> , 2020, 136, 25-26.	1.4	1
72	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. <i>Blood</i> , 2020, 136, 35-36.	1.4	0

#	ARTICLE	IF	CITATIONS
73	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. <i>Blood</i> , 2020, 136, 30-31.	1.4	0
74	Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis. <i>Blood</i> , 2020, 136, 19-20.	1.4	0
75	Impact of Allogeneic Stem Cell Transplant on Outcomes of Patients with Acute Myeloid Leukemia Based on NPM1 and FLT3 Mutational Status. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S113-S114.	2.0	1
76	Long-Term Outcomes after Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S193-S194.	2.0	0
77	Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1232-1239.	2.0	6
78	Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. <i>Annals of Hematology</i> , 2019, 98, 331-337.	1.8	5
79	Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 648-661.	2.4	14
80	Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e145-e154.	2.0	16
81	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 990-999.	1.3	9
82	Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 4560-4560.	1.4	1
83	Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucef Therapy for Lymphoma. <i>Blood</i> , 2019, 134, 4106-4106.	1.4	6
84	Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). <i>Blood</i> , 2019, 134, 5441-5441.	1.4	0
85	Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias. <i>Blood</i> , 2019, 134, 5406-5406.	1.4	0
86	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. <i>Blood</i> , 2019, 134, 3863-3863.	1.4	1
87	Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes. <i>Blood</i> , 2019, 134, 3300-3300.	1.4	0
88	Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. <i>Blood</i> , 2019, 134, 2588-2588.	1.4	0
89	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , 2018, 8, 18.	6.2	19
90	Outcome of Patients with Myelodysplastic Syndrome and a Monosomal Karyotype Following Allogeneic Stem Cell Transplant: Single Institution Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S239.	2.0	0

#	ARTICLE	IF	CITATIONS
91	Hemolytic Uremic Syndrome Associated With Escherichia coli O157 Infection in an Allogeneic Stem Cell Transplant Recipient. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2018, 2, 387-391.	2.4	3
92	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018, 93, E398-E401.	4.1	1
93	A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome. <i>Systematic Reviews</i> , 2018, 7, 144.	5.3	15
94	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. <i>American Journal of Hematology</i> , 2018, 93, E355-E357.	4.1	2
95	Incidence and Mortality Outcomes in Allogeneic Transplant-Associated Thrombotic Microangiopathy. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S329-S330.	2.0	3
96	Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 431-437.	3.9	20
97	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Lymphoblastic Leukemia/Lymphoma: The Mayo Clinic Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S237-S238.	2.0	0
98	A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results. <i>Blood</i> , 2018, 132, 1443-1443.	1.4	0
99	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. <i>Blood</i> , 2018, 132, 5510-5510.	1.4	0
100	The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia. <i>Blood</i> , 2018, 132, 5440-5440.	1.4	1
101	Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR. <i>Blood</i> , 2018, 132, 3456-3456.	1.4	0
102	66-Year-Old Woman With Falls and Confusion. <i>Mayo Clinic Proceedings</i> , 2017, 92, e15-e19.	3.0	2
103	The Impact of Febrile Neutropenia after Allogeneic Hematopoietic Cell Transplantation on Graft-Versus-Host Disease and Relapse in Patients with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S370-S371.	2.0	1
104	Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1478-1484.	2.0	31
105	Infectious Complications Associated with Infliximab Therapy for Allogeneic Stem Cell Transplant Patients with Corticosteroid Refractory Acute Graft Versus Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S200-S201.	2.0	1
106	Vancomycin-resistant <i>Enterococcus</i> colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. <i>Transplant Infectious Disease</i> , 2016, 18, 913-920.	1.7	40
107	61-Year-Old Man With Right Knee Pain and Chronic Anemia. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1640-1644.	3.0	0
108	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1431-1439.	2.0	26

#	ARTICLE	IF	CITATIONS
109	Cytomegalovirus Reactivation after Umbilical Cord Transplantation and Its Impact on Outcomes- a Mayo Clinic Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S314-S315.	2.0	0
110	Feasibility of Allogeneic Hematopoietic Stem Cell Transplant for High Risk FLT3-ITD Mutant Patients with Acute Myeloid Leukemia in CR1- a Real Word Analysis. <i>Blood</i> , 2016, 128, 4694-4694.	1.4	1
111	Clinical Outcomes Related to the Use of Monoclonal Antibody Therapy for Steroid Refractory Acute Graft-Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 4593-4593.	1.4	0
112	Monosomal Karyotype Predicts Adverse Prognosis in Patients Diagnosed With Chronic Myelomonocytic Leukemia: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e39-e41.	0.4	6
113	Prognostic impact of combined NPM1+/FLT3 <sup>ITD</sup> genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. <i>Leukemia Research</i> , 2015, 39, 1207-1213.	0.8	7
114	Comparative Analysis of Azacitidine and Decitabine in Myelodysplastic Syndromes: A Systematic Review and Network Meta-Analysis. <i>Blood</i> , 2015, 126, 1692-1692.	1.4	2
115	Early T-Lymphocyte Chimerism Kinetics Is Influenced By Conditioning Regimen in Reduced Intensity Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 1923-1923.	1.4	1
116	Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 3210-3210.	1.4	1
117	Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing. <i>Blood</i> , 2015, 126, 736-736.	1.4	2
118	A Phase II of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TASigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Interim Results. <i>Blood</i> , 2015, 126, 3808-3808.	1.4	0
119	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. <i>Blood</i> , 2015, 126, 3730-3730.	1.4	0
120	Response to Hypomethylating Agents in Myelodysplastic Syndromes Based on WHO 2008 Subtypes and IPSS-R Stratification and Impact on Survival. <i>Blood</i> , 2015, 126, 5260-5260.	1.4	0
121	Clinical Characteristics and Outcome of Adult Acute Erythroleukemia; Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4980-4980.	1.4	0
122	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. <i>Blood</i> , 2015, 126, 2490-2490.	1.4	0
123	Clofarabine Based Chemotherapy in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma-a Single Institution Experience. <i>Blood</i> , 2015, 126, 4910-4910.	1.4	0
124	Early CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1913-1913.	1.4	0
125	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. <i>Blood</i> , 2015, 126, 4993-4993.	1.4	0
126	Clinical Outcome of Hypomethylating Agents in Hypocellular MDS: Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 5254-5254.	1.4	0



#	ARTICLE	IF	CITATIONS
127	Clinical Outcome of Patients Diagnosed with Myelodysplastic Syndrome-Unclassifiable (MDS-U): Single Center Experience. Blood, 2014, 124, 3264-3264.	1.4	1
128	Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. Blood, 2013, 122, 4955-4955.	1.4	0
129	Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. Blood, 2013, 122, 1334-1334.	1.4	1
130	Tacrolimus Induced Refractory Immune Thrombocytopenia.. Blood, 2010, 116, 1426-1426.	1.4	3